{"product_id":"89bio-five-forces-analysis","title":"89bio Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003e89bio faces intense supplier and regulatory pressures typical of biopharma, moderate buyer bargaining from payers and partners, significant threat from biotech entrants with novel modalities, and limited substitutes for its niche therapies — all shaping a challenging competitive landscape.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore 89bio’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a clinical-stage company, 89bio depends on a small set of specialized contract manufacturing organizations (CMOs) to produce pegozafermin under strict cGMP rules; in 2025 only about 20 global sites handle complex glyco-PEGylation, concentrating capacity. \u003c\/p\u003e\n\u003cp\u003eThese CMOs require premium fees and long lead times—industry surveys show 6–12 month slot waits and 15–30% higher CMO pricing for PEGylated proteins—giving suppliers moderate-to-high bargaining power over 89bio’s timelines and COGS. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Proprietary Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDependence on proprietary site-specific glyco-PEGylation tech for pegozafermin ties 89bio to third-party IP, raising switching costs and making alternatives costly or slow to validate; if a single supplier controls key reagents, they gain leverage in renewals. By 2025, biotech supplier concentration saw top-5 reagent firms hold ~65% of market share, so exclusivity could materially raise COGS and margin pressure. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organization Reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe execution of Phase 3 trials like ENLIGHTEN and ENTRUST forces 89bio to rely on global clinical research organizations (CROs) that handle complex recruitment and data collection; top-tier CROs saw 2024 average day rates rise ~12% in metabolic trials, driven by a 35% increase in NASH\/MASH studies since 2020. High CRO demand lets providers charge premiums, so a partnership disruption could delay 89bio’s regulatory filing by 6–12+ months and materially affect cash burn and milestone timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Reagent Scarcity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe production of biologics needs high-quality cell culture media, specialized resins, and reagents that face supply volatility; in 2024 biotech raw-material lead times rose 28% and resin shortages pushed prices up ~15% versus 2022, giving suppliers leverage over smaller firms like 89bio.\u003c\/p\u003e\n\u003cp\u003eRegulatory-grade (GMP) materials for late-stage trials are tightly specified, so shortages can force 89bio to pay premiums or delay programs, increasing COGS and timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 lead times +28%\u003c\/li\u003e\n\u003cli\u003eResin price +15% vs 2022\u003c\/li\u003e\n\u003cli\u003eGMP grade = limited substitutes\u003c\/li\u003e\n\u003cli\u003eSmaller buyers face higher price risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe pool of scientists and regulatory experts for FGF21 and metabolic disorder programs is small; a 2024 survey found \u0026gt;60% of biotech hires with this specialty commanded 20–40% salary premiums versus general R\u0026amp;D roles.\u003c\/p\u003e\n\u003cp\u003eBig pharma and well-funded startups compete fiercely, raising retention costs and contracting rates; reported contractor day-rates reached $1,500–3,000 in 2024 for senior regulatory consultants.\u003c\/p\u003e\n\u003cp\u003eThat scarcity boosts bargaining power of key staff and consultants crucial for FDA and EMA filings, increasing 89bio’s operating risk and development spend during pivotal approval stages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialist salary premium: 20–40% (2024)\u003c\/li\u003e\n\u003cli\u003eSenior consultant rates: $1,500–3,000\/day (2024)\u003c\/li\u003e\n\u003cli\u003eHigh turnover risk raises development costs and approval timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: limited glyco-PEG CMOs, rising costs \u0026amp; 6–12+ month filing delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-high power: limited CMOs for glyco-PEGylation (≈20 global sites in 2025), 6–12 month slot waits, 15–30% higher pricing, and top-5 reagent firms ~65% share raise COGS risk; 2024 lead times +28% and resin prices +15% vs 2022; CRO day rates +12% in 2024 and senior consultants $1,500–3,000\/day—disruptions can delay filings 6–12+ months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlyco-PEGylation sites (2025)\u003c\/td\u003e\n\u003ctd\u003e≈20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO slot waits\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePEGylated protein premium\u003c\/td\u003e\n\u003ctd\u003e15–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 reagent share (2025)\u003c\/td\u003e\n\u003ctd\u003e≈65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead times (2024 vs 2022)\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResin price change (2024 vs 2022)\u003c\/td\u003e\n\u003ctd\u003e+15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO day-rate rise (2024)\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSenior consultant rates (2024)\u003c\/td\u003e\n\u003ctd\u003e$1,500–3,000\/day\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for 89bio, this Porter's Five Forces overview uncovers competitive drivers, supplier and buyer power, entry barriers, substitutes, and emerging threats shaping its biotech market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for 89bio—clarifying competitive threats and partnership leverage to speed strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUpon commercialization, 89bio will confront a highly consolidated set of pharmacy benefit managers (PBMs) and payers — the top three PBMs control roughly 80% of US prescription claims as of 2025 — who set formulary access for metabolic drugs and extract large rebates (often 20–40%+ of list price). Their scale lets them pit manufacturers against each other, so failing to win a favorable PBM tier could sharply restrict patient access to pegozafermin despite strong efficacy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Government Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare and Medicaid cover a large share of NASH and severe hypertriglyceridemia (SHTG) patients—about 35–45% of adults with metabolic liver disease fall into Medicare\/Medicaid cohorts—so government payers will materially influence uptake for 89bio’s lead candidate. The Inflation Reduction Act (2022) lets Medicare negotiate prices for top-spend drugs, and CBO estimates negotiated rebates could cut prices by 20–25% in affected categories, putting clear downward pressure on 89bio’s achievable net price and gross-to-net spreads.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician Prescription Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHepatologists and endocrinologists, not patients, drive prescribing for liver and cardiometabolic conditions, giving them high bargaining power via clinical autonomy and multiple drug-class options; speciality prescribers influence ~85% of NASH and cardiometabolic therapy starts per 2024 prescribing surveys. \u003c\/p\u003e\n\u003cp\u003e89bio must fund medical education and KOL engagement—estimated $20–40M over 3 years for launch-grade clinician outreach—to show pegozafermin’s superior biopsy and MRI-PDFF outcomes vs standard care. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Technology Assessment Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealth Technology Assessment agencies like NICE in the UK run strict cost-effectiveness reviews and can block or limit reimbursement for pegozafermin if price per quality-adjusted life year (QALY) exceeds thresholds—NICE used a ~20,000–30,000 GBP\/QALY guide in 2024.\u003c\/p\u003e\n\u003cp\u003e89bio must show clear QALY gains and budget impact reductions to preserve pricing power in socialized systems; failing that, market access and uptake in Europe could be restricted.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eNICE threshold ~20k–30k GBP\/QALY (2024)\u003c\/li\u003e\n\u003cli\u003eDemonstrate \u0026gt;acceptable QALY gains vs SOC\u003c\/li\u003e\n\u003cli\u003eInclude real-world budget impact models\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Group Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups for NASH (nonalcoholic steatohepatitis) are increasingly vocal on pricing and access, shaping public sentiment and policy; 2024 surveys show 62% of US NASH patients cite affordability as top concern, pushing payers and lawmakers to scrutinize launch prices.\u003c\/p\u003e\n\u003cp\u003eThey can boost uptake via awareness campaigns but also cap pricing power—recent advocacy-led negotiations cut list prices by 10–25% in comparable chronic disease launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of US NASH patients cite affordability (2024 survey)\u003c\/li\u003e\n\u003cli\u003eAdvocacy pressure has driven 10–25% price reductions in similar launches\u003c\/li\u003e\n\u003cli\u003eInfluences public perception, payer coverage, and political scrutiny\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ clout to slash pegozafermin net price and access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold strong leverage: top three PBMs control ~80% of US scripts (2025), Medicare\/Medicaid cover ~35–45% of metabolic patients, and specialty prescribers drive ~85% of starts, so formulary placement, negotiated rebates (20–40%+), and IRA Medicare negotiation (20–25% price cuts) will sharply constrain pegozafermin’s net price and access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-3 PBM share\u003c\/td\u003e\n\u003ctd\u003e~80% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Medicaid patient share\u003c\/td\u003e\n\u003ctd\u003e35–45% (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist-driven starts\u003c\/td\u003e\n\u003ctd\u003e~85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical manufacturer rebates\u003c\/td\u003e\n\u003ctd\u003e20–40%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated IRA price cut\u003c\/td\u003e\n\u003ctd\u003e20–25% (CBO est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e89bio Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact 89bio Porter's Five Forces analysis you'll receive after purchase—no placeholders or samples, fully formatted and ready to use. The document covers competitive rivalry, threat of new entrants, bargaining power of suppliers and buyers, and threat of substitutes with concise, actionable insights tailored to 89bio. Upon payment you’ll get immediate access to this identical file for download and implementation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747381522809,"sku":"89bio-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/89bio-five-forces-analysis.png?v=1772197865","url":"https:\/\/matrixbcg.com\/products\/89bio-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}